INS and type 2 diabetes mellitus: In two open-label, randomized, multicentric comparative (insulin) controlled trials in T2DM patients suboptimally controlled with metformin and a sulfonylurea, treatment with EX (5 μg twice-daily for 4 w and 10 μg thereafter) and an insulin analogue (glargine or biphasic insulin aspart) resulted in similar effects in HbA(1)c.